(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat ...

Recordati will acquire global rights to Enjaymo for $825M upfront and up to $250M in milestone payments. Enjaymo generated €100M in revenue in 2024 and is expected to exceed €150M in 2025 ...

Kepler Capital analyst Niccolo Guido Storer maintained a Hold rating on Recordati Industria Chimica e Farmaceutica SPA (0KBS – Research ...

Nine European nations are considered to be among the world’s most transparent countries, while just one North American country makes it into the top 10. [ SEE: The 25 Best Countries in the World ...

Recordati reached an agreement with French pharmaceutical company Sanofi to acquire the global rights to autoimmune disorder treatment Enjaymo for $825 million. The Italian pharmaceutical company ...

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company ...

Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic ...

Researchers turned skin and muscle tissues of live mice transparent by applying a yellow food dye known as tartrazine, which is commonly used in snack chips and candy coating. They found the ...

A new study has detailed how mice skin can be turned transparent to see inside their bodies while they are still alive. The new procedure doesn't harm the animals and involves the use of food dye ...

(Reuters) - Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 ...